Go Pro
→ Your $29.97 book is free today (From Profits Run) (Ad)tc pixel Free MREO Stock Alerts

Mereo BioPharma Group (MREO) Financials

Mereo BioPharma Group logo
$0.34 -0.01 (-1.96%)
As of 11:57 AM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare
Annual Income Statements for Mereo BioPharma Group

Annual Income Statements for Mereo BioPharma Group

This table shows Mereo BioPharma Group's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -35 -52 -42 -49 -447 34 -42 -29 -43 -42
Consolidated Net Income / (Loss)		 -35 -52 -41 -46 -223 17 -42 -29 -43 -42
Net Income / (Loss) Continuing Operations		 -35 -52 -42 -49 -223 17 -42 -29 -43 -42
Total Pre-Tax Income 		-42 -63 -48 -54 -223 17 -43 -30 -43 -42
Total Operating Income		 -45 -61 -44 -52 -47 -30 -54 -28 -47 -40
Total Gross Profit		 0.00 0.00 0.00 0.00 3.91 23 1.15 7.43 0.00 0.37
Total Revenue		 0.00 0.00 0.00 0.00 3.91 47 0.00 10 0.00 0.50
Operating Revenue		 - - - 0.00 3.91 47 0.00 10 0.00 0.50
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 24 -1.15 2.57 0.00 0.13
Operating Cost of Revenue		 - - - 0.00 0.00 24 -1.15 2.57 0.00 0.13
Total Operating Expenses		 45 61 44 52 51 53 56 36 47 41
Selling, General & Admin Expense		 14 14 15 21 29 22 26 18 26 23
Research & Development Expense		 30 47 29 31 22 32 29 17 21 18
Total Other Income / (Expense), net		 3.03 -2.22 -4.51 -4.65 -176 47 11 -1.57 4.11 -1.47
Interest Expense		 0.22 1.47 4.85 5.79 - - 4.18 2.88 1.37 0.26
Interest & Investment Income		 0.46 1.12 0.39 0.50 - - 0.84 2.13 3.04 2.17
Other Income / (Expense), net		 2.79 -1.87 -0.06 0.64 -176 47 15 -0.82 2.44 -3.39
Income Tax Expense		 -6.58 -11 -6.72 -8.31 - - -0.72 -0.53 0.00 0.00
Basic Earnings per Share		 - ($0.56) ($0.45) ($0.39) - - ($0.07) ($0.04) ($0.06) ($0.05)
Weighted Average Basic Shares Outstanding		 - - 71.24M 97.96M -0.48 0.02 603.20M 659.45M 739.62M 797.12M
Diluted Earnings per Share		 - ($0.56) ($0.45) ($0.39) - - ($0.07) ($0.04) ($0.06) ($0.05)
Weighted Average Diluted Shares Outstanding		 - - 71.24M 97.96M 338.95M 584.91M 603.20M 659.45M 739.62M 797.12M
Weighted Average Basic & Diluted Shares Outstanding		 - - 71.24M 97.96M 338.95M 584.91M 624.93M 701.29M 795.00M 798.08M

Quarterly Income Statements for Mereo BioPharma Group

This table shows Mereo BioPharma Group's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -6.53 -11 -8.95 -12 -15 -7.05 -13 -15 -7.02 -7.35 -6.72
Consolidated Net Income / (Loss)		 -6.53 -9.11 -8.95 -12 -15 -7.05 -13 -15 -7.02 -7.35 -6.72
Net Income / (Loss) Continuing Operations		 -6.53 -9.12 -8.95 -12 -15 -7.05 -13 -15 -7.02 -7.35 -6.72
Total Pre-Tax Income 		-6.53 -9.64 -8.95 -12 -15 -7.05 -13 -15 -7.02 -7.35 -6.72
Total Operating Income		 -9.07 -7.13 -9.90 -13 -9.37 -15 -11 -10 -10 -8.39 -8.77
Total Gross Profit		 0.24 1.62 0.00 0.00 0.00 - 0.00 0.37 0.00 -0.00 0.00
Total Revenue		 0.00 1.00 0.00 0.00 0.00 - 0.00 0.50 0.00 - 0.00
Operating Revenue		 0.00 1.00 0.00 0.00 0.00 - 0.00 0.50 0.00 - 0.00
Total Cost of Revenue		 -0.24 -0.62 0.00 0.00 0.00 - 0.00 0.13 0.00 0.00 0.00
Operating Cost of Revenue		 -0.24 - 0.00 0.00 0.00 - 0.00 0.13 0.00 0.00 0.00
Total Operating Expenses		 9.30 8.06 9.90 13 9.37 15 11 11 10 8.69 8.77
Selling, General & Admin Expense		 5.71 3.60 5.91 7.87 6.20 6.46 7.27 5.49 6.05 4.20 4.02
Research & Development Expense		 3.59 4.81 3.99 4.95 3.17 8.82 3.93 5.37 4.27 4.19 4.75
Other Operating Expenses / (Income)		 - - - - 0.00 - 0.00 - -0.30 - 0.00
Total Other Income / (Expense), net		 2.54 -3.21 0.95 0.56 -5.63 8.23 -1.69 -4.12 2.99 1.34 2.05
Interest Expense		 0.70 0.35 0.31 0.33 0.35 0.38 0.18 0.02 0.03 0.02 0.02
Interest & Investment Income		 0.69 0.76 0.62 0.56 0.98 0.88 0.66 0.59 0.50 0.42 0.33
Other Income / (Expense), net		 2.55 -3.62 0.64 0.33 -6.26 7.73 -2.16 -4.68 2.52 0.94 1.74
Income Tax Expense		 0.00 -0.53 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Basic Earnings per Share		 ($0.01) ($0.01) ($0.01) ($0.02) ($0.02) ($0.01) ($0.02) ($0.02) ($0.01) - ($0.01)
Weighted Average Basic Shares Outstanding		 684.97M 659.45M 700.26M 711.77M 770.15M 739.62M 784.28M 799.44M 799.95M 797.12M 801.81M
Diluted Earnings per Share		 ($0.01) ($0.01) ($0.01) ($0.02) ($0.02) ($0.01) ($0.02) ($0.02) ($0.01) - ($0.01)
Weighted Average Diluted Shares Outstanding		 684.97M 659.45M 700.26M 711.77M 770.15M 739.62M 784.28M 799.44M 799.95M 797.12M 801.81M
Weighted Average Basic & Diluted Shares Outstanding		 - 701.29M 701.36M 769.26M 775.73M 795.00M 795.00M 795.48M 795.66M 798.08M 798.09M

Annual Cash Flow Statements for Mereo BioPharma Group

This table details how cash moves in and out of Mereo BioPharma Group's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 48 -2.90 -32 -11 36 97 -47 -11 13 -31
Net Cash From Operating Activities		 -37 -43 -29 -61 2.18 -8.17 -49 -21 -33 -31
Net Cash From Continuing Operating Activities		 -35 -44 -28 -55 2.18 -8.17 -49 -21 -33 -31
Net Income / (Loss) Continuing Operations		 -42 -63 -48 -54 0.00 0.00 -42 -29 -43 -42
Consolidated Net Income / (Loss)		 -42 -63 -48 -54 - - -42 -29 -43 -42
Depreciation Expense		 0.04 0.05 0.05 2.09 2.18 - 0.18 0.17 0.14 0.16
Amortization Expense		 - - - - - - 0.71 0.89 0.95 0.99
Non-Cash Adjustments To Reconcile Net Income		 5.44 8.28 6.03 6.45 - -8.17 -9.48 9.32 8.05 14
Changes in Operating Assets and Liabilities, net		 1.17 11 13 -8.74 - - 1.99 -2.05 1.28 -4.60
Net Cash From Investing Activities		 0.46 -5.06 0.32 57 0.00 -0.72 1.99 -0.42 -0.70 -0.02
Net Cash From Continuing Investing Activities		 0.46 -5.06 0.32 44 0.00 -0.72 1.99 -0.42 -0.70 -0.02
Purchase of Property, Plant & Equipment		 -0.00 -3.10 -0.04 -0.03 - -0.72 -0.01 - 0.00 -0.02
Acquisitions		 - - - - - - 0.00 -0.42 -0.70 -0.30
Other Investing Activities, net		 0.46 -1.96 0.36 0.50 - - 2.00 - 0.00 0.30
Net Cash From Financing Activities		 84 46 -2.64 -7.57 34 106 0.20 7.97 46 0.33
Net Cash From Continuing Financing Activities		 84 46 -2.05 -7.57 34 106 0.20 7.97 46 0.33
Repayment of Debt		 0.00 -0.71 -2.10 -5.24 -27 0.00 0.00 -3.22 0.00 0.00
Repurchase of Common Equity		 -3.70 -0.99 -0.40 -2.33 - - 0.00 -0.51 -0.85 -0.20
Issuance of Common Equity		 84 20 0.35 0.00 0.00 - 0.20 12 47 0.04
Other Financing Activities, net		 0.00 0.00 0.10 0.00 0.00 0.06 0.00 - 0.00 0.49
Cash Interest Paid		 - - - - 3.96 0.00 0.02 0.88 0.02 0.03
Cash Income Taxes Paid		 - - - - - - 1.88 -1.34 0.00 0.00

Quarterly Cash Flow Statements for Mereo BioPharma Group

This table details how cash moves in and out of Mereo BioPharma Group's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 12 -5.11 -8.69 39 -7.09 -11 -8.23 -7.79 -7.01 -7.64 -4.61
Net Cash From Operating Activities		 2.66 -6.79 -7.99 -7.90 -7.52 -9.42 -8.33 -7.65 -7.31 -7.68 -4.31
Net Cash From Continuing Operating Activities		 2.66 -6.79 -7.95 -7.90 -7.52 -9.12 -8.33 -7.65 -7.31 -7.68 -4.31
Net Income / (Loss) Continuing Operations		 -6.53 -9.11 -8.95 -12 -15 -7.05 -13 -15 -7.02 -7.35 -6.72
Consolidated Net Income / (Loss)		 -6.53 -9.11 -8.95 -12 -15 -7.05 -13 -15 -7.02 -7.35 -6.72
Depreciation Expense		 0.05 0.04 0.04 0.02 0.04 0.04 0.04 0.04 0.04 0.04 0.04
Amortization Expense		 0.24 0.24 0.11 0.23 0.24 0.24 0.23 0.25 -0.05 0.56 0.26
Non-Cash Adjustments To Reconcile Net Income		 1.43 4.83 1.73 2.22 8.35 -3.78 5.75 6.77 0.99 0.85 -0.15
Changes in Operating Assets and Liabilities, net		 7.48 -2.79 -0.87 1.88 -1.16 1.43 -1.47 -0.10 -1.26 -1.77 2.26
Net Cash From Investing Activities		 - - -0.70 0.00 - - -0.32 - 0.30 - -0.30
Net Cash From Continuing Investing Activities		 - - -0.70 0.00 - - -0.32 - 0.30 - -0.30
Purchase of Property, Plant & Equipment		 - - 0.00 - - - -0.02 - - - 0.00
Acquisitions		 - - -0.70 0.00 - - -0.30 - - - -0.30
Other Investing Activities, net		 - - - - - - 0.00 - - - 0.00
Net Cash From Financing Activities		 7.91 - 0.00 47 -0.59 -0.04 0.42 -0.13 - 0.04 0.00
Net Cash From Continuing Financing Activities		 7.91 - 0.00 47 -0.59 -0.04 0.42 -0.13 - 0.04 0.00
Repurchase of Common Equity		 - - 0.00 - - - -0.07 -0.13 - - 0.00
Issuance of Common Equity		 12 - - - - - 0.00 - - 0.04 0.00
Other Financing Activities, net		 -0.51 - 0.00 - -0.59 - 0.49 - - - 0.00
Cash Interest Paid		 0.00 0.02 0.00 0.01 - 0.01 0.01 0.01 0.01 0.01 0.01

Annual Balance Sheets for Mereo BioPharma Group

This table presents Mereo BioPharma Group's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 130 86 115 86 171 77 66 76 46
Total Current Assets		 85 44 40 41 134 75 64 75 45
Cash & Equivalents		 68 32 22 32 127 68 57 70 41
Prepaid Expenses		 2.66 1.36 2.80 2.21 3.78 5.45 5.16 2.18 2.53
Other Current Assets		 - - - - - 1.57 1.18 2.79 1.50
Plant, Property, & Equipment, net		 0.21 0.19 15 2.15 3.42 0.55 0.41 0.26 0.14
Total Noncurrent Assets		 45 42 59 43 33 1.67 2.33 1.37 0.76
Intangible Assets		 45 42 59 43 33 0.00 1.09 0.64 0.52
Other Noncurrent Operating Assets		 - - - - - 1.67 1.25 0.73 0.24
Total Liabilities & Shareholders' Equity		 130 86 107 86 165 77 66 76 46
Total Liabilities		 46 44 61 106 52 26 16 15 5.00
Total Current Liabilities		 13 21 40 12 17 24 9.49 14 4.30
Short-Term Debt		 2.62 8.71 20 - 0.00 13 0.00 5.54 0.00
Accounts Payable		 4.09 5.82 8.42 4.55 3.37 3.49 2.35 2.44 1.33
Accrued Expenses		 5.92 5.65 - 5.71 - 5.44 5.47 4.07 2.03
Other Current Liabilities		 0.37 0.42 3.84 1.44 6.34 2.12 1.67 1.80 0.94
Total Noncurrent Liabilities		 33 23 22 95 35 1.64 6.48 1.57 0.70
Long-Term Debt		 25 19 7.12 22 19 0.00 4.39 0.00 0.00
Other Noncurrent Operating Liabilities		 7.32 4.69 2.15 71 13 1.64 2.08 1.57 0.70
Commitments & Contingencies		 - - - - - 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 84 42 53 -20 119 51 51 61 41
Total Preferred & Common Equity		 84 42 53 -20 119 51 51 61 41
Total Common Equity		 -75 -109 -108 -241 -215 51 51 61 41
Common Stock		 0.29 0.27 0.39 1.39 2.37 479 489 543 553
Retained Earnings		 -107 -142 -194 -423 -401 -405 -420 -463 -501
Accumulated Other Comprehensive Income / (Loss)		 - - - - - -22 -17 -19 -11

Quarterly Balance Sheets for Mereo BioPharma Group

This table presents Mereo BioPharma Group's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 56 96 89 68 63 54 41
Total Current Assets		 53 94 87 67 61 52 40
Cash & Equivalents		 49 87 81 62 56 49 36
Prepaid Expenses		 3.19 4.49 3.83 2.52 2.55 2.69 2.25
Other Current Assets		 1.65 2.02 2.37 1.90 2.75 1.02 1.56
Plant, Property, & Equipment, net		 0.36 0.34 0.32 0.25 0.22 0.17 0.09
Total Noncurrent Assets		 2.08 1.85 1.71 1.18 0.99 1.02 0.49
Intangible Assets		 0.97 0.87 0.80 0.55 0.47 0.64 0.38
Other Noncurrent Operating Assets		 1.11 0.99 0.91 0.62 0.52 0.38 0.11
Total Liabilities & Shareholders' Equity		 56 96 89 68 63 54 41
Total Liabilities		 13 17 16 8.24 8.45 7.00 6.56
Total Current Liabilities		 11 15 14 7.50 7.56 6.02 6.18
Short-Term Debt		 4.63 4.93 5.55 0.00 0.00 0.00 0.00
Accounts Payable		 2.46 2.70 1.75 2.92 1.14 0.88 3.23
Accrued Expenses		 2.54 3.72 3.53 2.93 5.04 4.12 2.05
Other Current Liabilities		 1.38 4.11 3.38 1.64 1.38 1.02 0.91
Total Noncurrent Liabilities		 2.10 2.01 2.00 0.74 0.90 0.99 0.38
Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Other Noncurrent Operating Liabilities		 2.10 2.01 2.00 0.74 0.90 0.99 0.38
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 43 79 73 60 54 47 34
Total Preferred & Common Equity		 43 79 73 60 54 47 34
Total Common Equity		 43 79 73 60 54 47 34
Common Stock		 490 538 539 547 549 551 554
Retained Earnings		 -429 -441 -456 -472 -487 -494 -508
Accumulated Other Comprehensive Income / (Loss)		 -18 -18 -11 -15 -8.64 -11 -13

Annual Metrics And Ratios for Mereo BioPharma Group

This table displays calculated financial ratios and metrics derived from Mereo BioPharma Group's official financial filings.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 - - - - - - - - - 795,658,504.00
DEI Adjusted Shares Outstanding		 - - - - - - - - - 795,658,504.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - - - -0.05
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 1,105.41% -100.00% 0.00% -100.00% 0.00%
EBITDA Growth		 0.00% -50.74% 30.29% -12.98% -345.84% 107.76% -325.36% 27.22% -55.57% 3.40%
EBIT Growth		 0.00% -50.71% 30.27% -17.61% -332.05% 107.69% -330.53% 26.17% -53.65% 3.18%
NOPAT Growth		 0.00% -37.10% 28.23% -19.21% 9.49% 8.64% -25.70% 47.79% -66.68% 15.32%
Net Income Growth		 0.00% -49.63% 22.15% -13.15% -384.00% 107.69% -345.77% 30.21% -46.79% 3.18%
EPS Growth		 0.00% 0.00% 19.64% 13.33% 0.00% 0.00% 0.00% 42.86% -50.00% 16.67%
Operating Cash Flow Growth		 0.00% -18.66% 32.12% -106.46% 103.59% -474.13% -497.55% 56.72% -55.38% 5.67%
Free Cash Flow Firm Growth		 0.00% 0.00% 72.34% -247.80% 191.46% -204.66% 79.15% -28.82% -55.10% 3.25%
Invested Capital Growth		 0.00% 0.00% -17.91% 130.62% -136.79% 163.92% -118.72% 27.91% -32.45% 97.70%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -100.00% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 6.80% 0.98%
EBIT Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 6.66% 0.24%
NOPAT Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -20.78% 14.65%
Net Income Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 4.55% -0.73%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 16.67%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -8.71% 5.31%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 5.82%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -35.44% 96.38%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 100.00% 48.76% 0.00% 74.26% 0.00% 73.40%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% -5,653.49% 36.41% 0.00% -281.77% 0.00% -8,469.40%
Operating Margin		 0.00% 0.00% 0.00% 0.00% -1,210.85% -64.24% 0.00% -284.16% 0.00% -8,021.40%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% -5,709.28% 36.41% 0.00% -292.38% 0.00% -8,699.20%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% -5,709.28% 36.41% 0.00% -294.66% 0.00% -8,375.60%
Tax Burden Percent		 84.19% 82.64% 85.85% 84.74% 100.00% 100.00% 98.33% 98.23% 100.00% 100.00%
Interest Burden Percent		 99.42% 100.56% 108.06% 105.34% 100.00% 100.00% 108.42% 102.60% 96.28% 96.28%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% -133.73% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% -2,410.19% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% -1,224.89% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 0.00% -62.09% -64.69% -97.11% -1,358.62% 34.93% -49.61% -57.81% -77.58% -82.21%
Cash Return on Invested Capital (CROIC)		 0.00% -406.66% -61.78% -144.17% 0.00% -420.68% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% -222.89% 13.39% 0.00% -40.63% 0.00% -71.13%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% -222.89% 13.39% 0.00% -40.95% 0.00% -68.48%
Return on Common Equity (ROCE)		 0.00% 55.40% 94.61% 221.71% 14,425.93% -162.19% 47.76% -57.81% -77.58% -82.21%
Return on Equity Simple (ROE_SIMPLE)		 0.00% -62.09% -97.74% -86.56% 1,092.97% 14.46% -82.14% -58.31% -70.94% 0.00%
Net Operating Profit after Tax (NOPAT)		 -31 -43 -31 -37 -33 -30 -38 -20 -33 -28
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% -847.60% -64.24% 0.00% -198.91% 0.00% -5,614.98%
Net Nonoperating Expense Percent (NNEP)		 0.00% -44.58% -39.70% 109.22% 2,276.45% 87.31% -5.31% -17.75% -17.22% -26.23%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - -36.21% -49.85% -68.62%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 51.24% 0.00% 25.74% 0.00% 26.60%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 740.47% 45.59% 0.00% 184.24% 0.00% 4,601.60%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 570.38% 67.41% 0.00% 174.18% 0.00% 3,553.20%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 1,310.85% 113.00% 0.00% 358.42% 0.00% 8,154.80%
Earnings before Interest and Taxes (EBIT)		 -42 -63 -44 -52 -223 17 -40 -29 -45 -43
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -42 -63 -44 -50 -221 17 -39 -28 -44 -42
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.00 0.00 0.00 0.00 1.71 5.71 8.91 1.62
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.00 0.00 0.00 1.71 5.84 9.00 1.64
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 17.92 2.30 0.00 28.87 0.00 132.62
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 3.16 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 31.68% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 2.88 0.00 18.26 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 72.22 7.14 0.00 23.57 0.00 50.64
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 19.62 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 19.62 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 129.44 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 3.81 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 0.00 0.33 0.66 0.74 -1.16 0.18 0.26 0.09 0.09 0.00
Long-Term Debt to Equity		 0.00 0.30 0.45 0.36 -1.16 0.18 0.00 0.09 0.00 0.00
Financial Leverage		 0.00 -0.51 -0.40 0.18 0.51 -1.11 -0.91 -1.06 -1.05 -1.03
Leverage Ratio		 0.00 1.54 1.71 2.11 6.10 2.61 1.46 1.41 1.28 1.20
Compound Leverage Factor		 0.00 1.55 1.85 2.22 6.10 2.61 1.58 1.45 1.23 1.16
Debt to Total Capital		 0.00% 24.93% 39.60% 42.56% 742.81% 15.50% 20.59% 8.00% 8.32% 0.00%
Short-Term Debt to Total Capital		 0.00% 2.33% 12.60% 21.60% 0.00% 0.00% 20.59% 0.00% 8.32% 0.00%
Long-Term Debt to Total Capital		 0.00% 22.60% 27.00% 20.96% 742.81% 15.50% 0.00% 8.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 142.04% 218.39% 173.62% 6,946.54% 237.62% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 0.00% -66.97% -157.99% -116.18% -7,589.35% -153.12% 79.41% 92.00% 91.68% 100.00%
Debt to EBITDA		 0.00 -0.44 -0.62 -0.80 -0.11 1.27 -0.34 -0.16 -0.13 0.00
Net Debt to EBITDA		 0.00 0.68 0.18 -0.36 0.04 -6.14 1.42 1.88 1.47 0.00
Long-Term Debt to EBITDA		 0.00 -0.40 -0.42 -0.39 -0.11 1.27 0.00 -0.16 0.00 0.00
Debt to NOPAT		 0.00 -0.65 -0.89 -1.08 -0.71 -0.72 -0.35 -0.22 -0.17 0.00
Net Debt to NOPAT		 0.00 1.00 0.25 -0.49 0.25 3.48 1.44 2.67 1.94 0.00
Long-Term Debt to NOPAT		 0.00 -0.59 -0.61 -0.53 -0.71 -0.72 0.00 -0.22 0.00 0.00
Altman Z-Score		 0.00 0.00 0.00 -3.39 -14.62 -0.60 -6.19 1.70 11.66 -9.37
Noncontrolling Interest Sharing Ratio		 0.00% 189.21% 246.25% 328.31% 1,161.81% 564.30% 196.28% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 0.00 6.57 2.13 1.02 3.47 7.92 3.09 6.72 5.40 10.46
Quick Ratio		 0.00 5.52 1.74 0.57 2.86 7.63 2.80 6.05 5.04 9.53
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -84 -23 -81 74 -78 -16 -21 -32 -31
Operating Cash Flow to CapEx		 -1,294,153.94% -1,400.22% -68,056.39% -218,716.53% 0.00% -1,131.22% -375,546.15% 0.00% 0.00% -154,855.00%
Free Cash Flow to Firm to Interest Expense		 0.00 -57.25 -4.81 -14.00 0.00 0.00 -3.88 -7.24 -23.61 -122.73
Operating Cash Flow to Interest Expense		 -165.01 -29.49 -6.08 -10.51 0.00 0.00 -11.69 -7.34 -23.97 -121.45
Operating Cash Flow Less CapEx to Interest Expense		 -165.02 -31.60 -6.09 -10.51 0.00 0.00 -11.70 -7.34 -23.97 -121.53
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.04 0.37 0.00 0.14 0.00 0.01
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 3.65 28.57 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.45 16.96 0.00 20.92 0.00 2.54
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 6.10 0.00 0.88 0.00 0.07
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 100.04 12.78 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 59.83 0.00 413.92 0.00 5,177.24
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 100.04 -47.05 0.00 -413.92 0.00 -5,177.24
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 0.00 41 34 78 -29 18 -3.45 -2.49 -3.30 -0.08
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.16 -9.06 0.00 -3.36 0.00 -0.30
Increase / (Decrease) in Invested Capital		 0.00 41 -7.43 44 -107 47 -22 0.96 -0.81 3.22
Enterprise Value (EV)		 0.00 0.00 0.00 226 283 337 33 236 479 25
Market Capitalization		 0.00 0.00 0.00 47 70 108 88 289 543 66
Book Value per Share		 $0.00 $0.00 ($1.53) ($1.51) ($2.46) ($0.64) $0.09 $0.08 $0.08 $0.05
Tangible Book Value per Share		 $0.00 $0.00 ($2.12) ($2.34) ($2.91) ($0.73) $0.09 $0.08 $0.08 $0.05
Total Capital		 0.00 112 69 93 3.18 141 65 55 67 41
Total Debt		 0.00 28 27 40 24 22 13 4.39 5.54 0.00
Total Long-Term Debt		 0.00 25 19 19 24 22 0.00 4.39 0.00 0.00
Net Debt		 0.00 -43 -7.72 18 -8.43 -106 -55 -53 -64 -41
Capital Expenditures (CapEx)		 0.00 3.10 0.04 0.03 0.00 0.72 0.01 0.00 0.00 0.02
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 3.99 -3.04 -0.86 -3.15 -10 -4.03 -3.15 -3.35 -0.27
Debt-free Net Working Capital (DFNWC)		 0.00 75 32 21 29 117 64 54 66 41
Net Working Capital (NWC)		 0.00 72 23 0.74 29 117 51 54 61 41
Net Nonoperating Expense (NNE)		 3.78 9.57 10 9.52 190 -47 4.12 9.57 10 14
Net Nonoperating Obligations (NNO)		 0.00 -43 -7.72 25 -8.43 -100 -55 -53 -64 -41
Total Depreciation and Amortization (D&A)		 0.04 0.05 0.05 2.09 2.18 0.00 0.89 1.06 1.09 1.15
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% -80.53% -21.50% 0.00% -31.47% 0.00% -54.80%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 738.35% 248.31% 0.00% 542.74% 0.00% 8,143.60%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 738.35% 248.31% 0.00% 542.74% 0.00% 8,143.60%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 $0.00 ($0.39) ($0.48) $0.00 $0.00 ($0.04) ($0.06) ($0.05)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 71.24M 97.96M 338.95M 0.00 0.00 659.45M 739.62M 797.12M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $0.00 ($0.39) ($0.48) $0.00 $0.00 ($0.04) ($0.06) ($0.05)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 71.24M 97.96M 338.95M 584.91M 624.93M 659.45M 739.62M 797.12M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 ($0.39) ($0.48) $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 71.24M 97.96M 338.95M 584.91M 624.93M 701.29M 795.00M 798.08M
Normalized Net Operating Profit after Tax (NOPAT)		 -31 -43 -31 -37 -33 -21 -38 -20 -33 -28
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% -847.60% -44.97% 0.00% -198.91% 0.00% -5,614.98%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% -5,709.28% 36.41% 0.00% -299.98% 0.00% -8,375.60%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 -188.67 -42.83 -9.07 -8.93 0.00 0.00 -9.49 -10.15 -32.79 -170.57
NOPAT to Interest Expense		 -140.88 -29.09 -6.34 -6.33 0.00 0.00 -9.13 -6.90 -24.20 -110.10
EBIT Less CapEx to Interest Expense		 -188.69 -44.94 -9.08 -8.94 0.00 0.00 -9.49 -10.15 -32.79 -170.65
NOPAT Less CapEx to Interest Expense		 -140.89 -31.20 -6.35 -6.33 0.00 0.00 -9.13 -6.90 -24.20 -110.18
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -10.55% -1.88% -0.98% -5.05% 0.00% 0.00% 0.00% -1.73% -1.97% -0.48%

Quarterly Metrics And Ratios for Mereo BioPharma Group

This table displays calculated financial ratios and metrics derived from Mereo BioPharma Group's official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 - - - - - - 795,001,444.00 795,001,444.00 795,484,404.00 795,658,504.00 798,078,829.00
DEI Adjusted Shares Outstanding		 - - - - - - 795,001,444.00 795,001,444.00 795,484,404.00 795,658,504.00 798,078,829.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - -0.02 -0.02 -0.01 -0.01 -0.01
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% -100.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 0.00% 0.00% 15.63% -1,383.74% -146.06% 30.47% -43.77% -20.49% 50.25% 5.78% 48.68%
EBIT Growth		 0.00% 0.00% 14.86% -1,040.00% -139.74% 29.74% -44.37% -21.61% 52.02% 1.36% 47.43%
NOPAT Growth		 0.00% 0.00% 13.23% -1,480.02% -3.37% -114.32% -13.15% 18.07% -6.85% 45.07% 21.75%
Net Income Growth		 0.00% 0.00% 25.88% -599.89% -129.69% 22.64% -43.97% -19.27% 53.18% -4.33% 47.86%
EPS Growth		 0.00% 0.00% 50.00% 0.00% -100.00% 0.00% -100.00% 0.00% 50.00% 0.00% 50.00%
Operating Cash Flow Growth		 0.00% 0.00% 13.59% -1.93% -382.78% -38.75% -4.23% 3.20% 2.79% 18.45% 48.23%
Free Cash Flow Firm Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -15.57% -80.70% -78.03% 7.99% 3.95%
Invested Capital Growth		 0.00% 0.00% 0.00% 0.00% 0.00% -32.45% -101.51% 49.40% 13.76% 97.70% 9.70%
Revenue Q/Q Growth		 -100.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -100.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -657.04% -67.81% 0.00% -36.10% -25.54% 52.58% -79.94% -13.65% 49.53% 8.71% 1.98%
EBIT Q/Q Growth		 -495.43% -64.86% 0.00% -34.83% -25.22% 51.69% -76.99% -13.58% 50.60% 0.68% 5.68%
NOPAT Q/Q Growth		 -1,018.00% 21.39% 0.00% -29.43% 26.85% -62.99% 26.67% 6.28% 4.61% 16.22% -4.47%
Net Income Q/Q Growth		 -272.99% -39.46% 0.00% -36.91% -22.41% 53.03% -82.90% -13.42% 51.94% -4.66% 8.60%
EPS Q/Q Growth		 0.00% 0.00% 0.00% -100.00% 0.00% 50.00% -100.00% 0.00% 50.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 134.29% -355.32% 0.00% 1.09% 4.87% -25.28% 11.58% 8.14% 4.47% -5.10% 43.87%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 10.77% 19.41% -139.59% 32.92% -39.51% 20.60% -23.83% 29.98%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00% -222.99% 36.75% -35.44% 27.17% 18.90% -7.80% 96.38% -2,753.95%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 162.10% 0.00% 0.00% 0.00% 0.00% 0.00% 73.60% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% -1,046.80% 0.00% 0.00% 0.00% 0.00% 0.00% -2,976.60% 0.00% 0.00% 0.00%
Operating Margin		 0.00% -712.80% 0.00% 0.00% 0.00% 0.00% 0.00% -2,099.80% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% -1,074.90% 0.00% 0.00% 0.00% 0.00% 0.00% -3,036.20% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% -910.80% 0.00% 0.00% 0.00% 0.00% 0.00% -2,923.20% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 94.48% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 100.17% 89.68% 96.68% 98.17% 95.97% 93.30% 96.42% 96.28% 93.65% 98.68% 95.63%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 0.00% -57.81% -61.49% -46.85% -62.47% -77.58% -91.70% -74.61% -69.79% -82.21% -75.87%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% -149.38% 0.00% 0.00% 0.00% 0.00% 0.00% -19.12% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% -126.58% 0.00% 0.00% 0.00% 0.00% 0.00% -18.41% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 0.00% -57.81% -61.49% -46.85% -62.47% -77.58% -91.70% -74.61% -69.79% -82.21% -75.87%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 0.00% -61.49% -46.85% -62.47% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -6.35 -4.99 -6.93 -8.97 -6.56 -11 -7.84 -7.35 -7.01 -5.87 -6.14
NOPAT Margin		 0.00% -498.96% 0.00% 0.00% 0.00% 0.00% 0.00% -1,469.86% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 0.00% -7.77% -9.18% -7.96% -22.52% 6.22% -9.47% -10.48% -0.02% -2.81% -1.18%
Return On Investment Capital (ROIC_SIMPLE)		 - -9.08% - - - -16.08% -13.05% -13.57% -15.04% -14.36% -18.02%
Cost of Revenue to Revenue		 0.00% -62.10% 0.00% 0.00% 0.00% 0.00% 0.00% 26.40% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 359.70% 0.00% 0.00% 0.00% 0.00% 0.00% 1,098.80% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 480.50% 0.00% 0.00% 0.00% 0.00% 0.00% 1,074.60% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 805.50% 0.00% 0.00% 0.00% 0.00% 0.00% 2,173.40% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -6.52 -11 -9.26 -12 -16 -7.55 -13 -15 -7.50 -7.45 -7.03
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -6.24 -10 -8.98 -12 -15 -7.28 -13 -15 -7.51 -6.86 -6.72
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 5.71 10.80 6.42 8.72 8.91 5.95 7.95 7.03 1.62 1.55
Price to Tangible Book Value (P/TBV)		 0.00 5.84 11.06 6.49 8.81 9.00 6.01 8.02 7.13 1.64 1.56
Price to Revenue (P/Rev)		 0.00 28.87 46.28 504.98 632.33 0.00 0.00 861.78 655.48 132.62 105.35
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 23.57 41.88 422.48 557.36 0.00 0.00 749.53 558.08 50.64 32.90
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.09 0.11 0.06 0.08 0.09 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.09 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 0.00 -1.05 -1.03 -1.05 -1.03 -1.05 -1.03 -1.04 -1.04 -1.03 -1.05
Leverage Ratio		 0.00 1.41 1.31 1.22 1.22 1.28 1.21 1.20 1.19 1.20 1.16
Compound Leverage Factor		 0.00 1.27 1.26 1.20 1.17 1.20 1.16 1.15 1.12 1.18 1.11
Debt to Total Capital		 0.00% 8.00% 9.75% 5.90% 7.11% 8.32% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 9.75% 5.90% 7.11% 8.32% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 8.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 0.00% 92.00% 90.25% 94.10% 92.89% 91.68% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 -0.16 -0.17 -0.13 -0.12 -0.13 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 1.88 1.66 2.18 1.59 1.47 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 -0.16 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 -0.22 -0.25 -0.18 -0.20 -0.17 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 2.67 2.34 3.03 2.73 1.94 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 -0.22 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 0.00 2.61 11.02 11.48 16.62 13.27 16.77 19.94 15.77 -6.78 -12.24
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 0.00 6.72 4.86 6.07 6.10 5.40 8.92 8.13 8.71 10.46 6.48
Quick Ratio		 0.00 6.05 4.42 5.65 5.67 5.04 8.33 7.43 8.09 9.53 5.86
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 0.00 -5.74 -5.12 -4.13 -9.89 -6.63 -9.25 -7.35 -9.10 -6.37
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -41,645.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 -18.51 -15.47 -11.69 -26.29 -36.84 -385.47 -262.34 -395.47 -318.46
Operating Cash Flow to Interest Expense		 3.80 -19.29 -25.78 -23.88 -21.30 -25.05 -46.27 -318.79 -261.04 -334.00 -215.60
Operating Cash Flow Less CapEx to Interest Expense		 3.80 -19.29 -25.78 -23.88 -21.30 -25.05 -46.38 -318.79 -261.04 -334.00 -215.60
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.14 0.18 0.01 0.01 0.00 0.00 0.01 0.01 0.01 0.01
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 20.92 27.78 2.96 3.17 0.00 0.00 1.80 2.05 2.54 2.96
Accounts Payable Turnover		 0.00 0.88 1.05 0.00 0.00 0.00 0.00 0.07 0.10 0.07 0.04
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 413.92 348.13 0.00 0.00 0.00 0.00 5,306.33 3,632.03 5,177.24 8,438.91
Cash Conversion Cycle (CCC)		 0.00 -413.92 -348.13 0.00 0.00 0.00 0.00 -5,306.33 -3,632.03 -5,177.24 -8,438.91
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 0.00 -2.49 -1.19 -3.85 -2.44 -3.30 -2.40 -1.95 -2.10 -0.08 -2.17
Invested Capital Turnover		 0.00 -4.02 -16.78 -0.52 -0.82 0.00 0.00 -0.17 -0.22 -0.30 -0.22
Increase / (Decrease) in Invested Capital		 0.00 0.00 -1.19 -3.85 -2.44 -0.81 -1.21 1.90 0.34 3.22 0.23
Enterprise Value (EV)		 0.00 236 419 422 557 479 295 375 279 25 16
Market Capitalization		 161 289 463 505 632 543 358 431 328 66 53
Book Value per Share		 $0.00 $0.08 $0.06 $0.11 $0.09 $0.08 $0.08 $0.07 $0.06 $0.05 $0.04
Tangible Book Value per Share		 $0.00 $0.08 $0.06 $0.11 $0.09 $0.08 $0.07 $0.07 $0.06 $0.05 $0.04
Total Capital		 0.00 55 47 84 78 67 60 54 47 41 34
Total Debt		 0.00 4.39 4.63 4.93 5.55 5.54 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 4.39 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 0.00 -53 -44 -83 -75 -64 -62 -56 -49 -41 -36
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00 0.00 0.00 0.02 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 -3.15 -1.54 -4.03 -2.46 -3.35 -3.08 -2.26 -2.31 -0.27 -2.37
Debt-free Net Working Capital (DFNWC)		 0.00 54 47 83 78 66 59 54 46 41 34
Net Working Capital (NWC)		 0.00 54 42 78 73 61 59 54 46 41 34
Net Nonoperating Expense (NNE)		 0.18 4.12 2.02 3.29 8.44 -3.65 5.05 7.27 0.01 1.48 0.58
Net Nonoperating Obligations (NNO)		 0.00 -53 -44 -83 -75 -64 -62 -56 -49 -41 -36
Total Depreciation and Amortization (D&A)		 0.28 0.28 0.28 0.26 0.28 0.27 0.27 0.30 -0.01 0.59 0.31
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% -31.47% -15.38% -402.60% -245.60% 0.00% 0.00% -452.20% -461.40% -54.80% -473.20%
Debt-free Net Working Capital to Revenue		 0.00% 542.74% 471.22% 8,340.50% 7,806.60% 0.00% 0.00% 10,772.80% 9,278.20% 8,143.60% 6,771.40%
Net Working Capital to Revenue		 0.00% 542.74% 424.92% 7,847.40% 7,251.50% 0.00% 0.00% 10,772.80% 9,278.20% 8,143.60% 6,771.40%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($0.01) ($0.01) ($0.02) ($0.02) ($0.01) ($0.02) ($0.02) ($0.01) $0.00 ($0.01)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 659.45M 700.26M 711.77M 770.15M 739.62M 784.28M 799.44M 799.95M 797.12M 801.81M
Adjusted Diluted Earnings per Share		 $0.00 ($0.01) ($0.01) ($0.02) ($0.02) ($0.01) ($0.02) ($0.02) ($0.01) $0.00 ($0.01)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 659.45M 700.26M 711.77M 770.15M 739.62M 784.28M 799.44M 799.95M 797.12M 801.81M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 701.29M 701.36M 769.26M 775.73M 795.00M 795.00M 795.48M 795.66M 798.08M 798.09M
Normalized Net Operating Profit after Tax (NOPAT)		 -6.35 -4.99 -6.93 -8.97 -6.56 -11 -7.84 -7.35 -7.01 -5.87 -6.14
Normalized NOPAT Margin		 0.00% -498.96% 0.00% 0.00% 0.00% 0.00% 0.00% -1,469.86% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% -964.00% 0.00% 0.00% 0.00% 0.00% 0.00% -2,923.20% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -9.31 -30.54 -29.86 -37.71 -44.28 -20.09 -74.26 -632.54 -267.86 -323.87 -351.30
NOPAT to Interest Expense		 -9.07 -14.18 -22.35 -27.10 -18.59 -28.44 -43.56 -306.22 -250.38 -255.38 -306.81
EBIT Less CapEx to Interest Expense		 -9.31 -30.54 -29.86 -37.71 -44.28 -20.09 -74.37 -632.54 -267.86 -323.87 -351.30
NOPAT Less CapEx to Interest Expense		 -9.07 -14.18 -22.35 -27.10 -18.59 -28.44 -43.67 -306.22 -250.38 -255.38 -306.81
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% -1.73% 0.00% 0.00% 0.00% -1.97% -1.95% -1.68% -0.57% -0.48% -0.38%

Financials Breakdown Chart

Key Financial Trends

Mereo BioPharma Group (NASDAQ: MREO) remains a cash-rich biotech, but its quarterly results continue to show a business that is still heavily dependent on financing and other non-operating income rather than product sales. Over the last four years, revenue has been minimal and inconsistent, operating losses have persisted, and cash has steadily trended lower despite periodic equity raises and other balance-sheet support.

  • Strong cash position at quarter-end: Mereo ended Q1 2026 with $36.2 million in cash and equivalents and no short-term or long-term debt, which gives it flexibility compared with many development-stage biotechs.
  • Debt-free balance sheet: The company reported $0 in short-term debt and $0 in long-term debt in Q1 2026, reducing balance-sheet risk.
  • Equity still comfortably exceeds liabilities: Total equity was $34.1 million versus total liabilities of $6.6 million in Q1 2026, indicating the company is not under immediate solvency pressure.
  • Operating cash burn improved sequentially: Net cash used in operations improved to $4.3 million in Q1 2026 from $7.7 million in Q4 2025 and $7.3 million in Q3 2025.
  • Quarterly loss narrowed versus prior quarter: Net loss improved to $6.7 million in Q1 2026 from $7.4 million in Q4 2025.
  • No meaningful revenue trend yet: Revenue was $0 in Q1 2026, after a small $0.5 million in Q2 2025 and $1.0 million in Q4 2024, so the business still lacks a stable commercial sales base.
  • Non-operating items materially affect results: In Q1 2026, “other income, net” contributed $1.74 million, helping offset operating losses. That means earnings are still being driven partly by non-core items.
  • Shares outstanding remain high: Weighted average diluted shares were about 801.8 million in Q1 2026, which can make per-share growth harder to achieve.
  • Persistent operating losses: Mereo posted an operating loss of $8.8 million in Q1 2026, following a $8.4 million loss in Q4 2025 and a $10.0 million loss in Q3 2025.
  • Cash balance has declined sharply over the last year: Cash fell from $62.5 million in Q1 2025 to $36.2 million in Q1 2026, reflecting continued burn.

Longer-term picture: The last four years show a company that has repeatedly run negative earnings and negative operating cash flow. Quarterly net losses have generally ranged from roughly $6 million to $15 million, while operating cash flow has often been negative by $7 million to $9 million per quarter. Although Mereo has occasionally raised equity or benefited from favorable non-operating items, those sources have not yet translated into a durable profit model.

Bottom line: Mereo BioPharma’s balance sheet is still viable and debt-free, which is important for a clinical-stage biotech. But the ongoing cash burn, lack of consistent revenue, and dependence on non-operating income make the stock a higher-risk story until it can show clearer commercial progress or a sustained reduction in losses.

08/03/26 09:25 AM ETAI Generated. May Contain Errors.

Mereo BioPharma Group Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Mereo BioPharma Group's financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Mereo BioPharma Group's net income appears to be on a downward trend, with a most recent value of -$41.88 million in 2025, rising from -$35.03 million in 2016. The previous period was -$43.25 million in 2024. See Mereo BioPharma Group's forecast for analyst expectations on what's next for the company.

Mereo BioPharma Group's total operating income in 2025 was -$40.11 million, based on the following breakdown:
  • Total Gross Profit: $367 thousand
  • Total Operating Expenses: $40.77 million

Over the last 9 years, Mereo BioPharma Group's total revenue changed from $0.00 in 2016 to $500 thousand in 2025, a change of 50,000,000.0%.

Mereo BioPharma Group's total liabilities were at $5.00 million at the end of 2025, a 67.6% decrease from 2024, and a 89.1% decrease since 2017.

In the past 8 years, Mereo BioPharma Group's cash and equivalents has ranged from $21.66 million in 2019 to $127.30 million in 2021, and is currently $40.99 million as of their latest financial filing in 2025.

Over the last 9 years, Mereo BioPharma Group's book value per share changed from 0.00 in 2016 to 0.05 in 2025, a change of 5.1%.


Related Companies

Financial statements for NASDAQ:MREO last updated on 7/16/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel
Where to Put $100 Before Trump's New Tech Law Rolls Out
The Financial Times says a new tech law puts America 'on the verge of a financial revolution.' Yahoo Finance e...
Brownstone Research | Sponsoredtc pixel
Elon's new "super startup"
Adam O'Dell - the analyst who recommended Palantir before it became the top S&P 500 performer - has identified...
Banyan Hill Publishing | Sponsoredtc pixel
“The unseen winner of the AI race” is not SpaceX
Marc Chaikin - the analyst who called Nvidia before its historic run - says a tech firm labeled 'the unseen wi...
Chaikin Analytics | Sponsoredtc pixel